Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B vaccine (recombinant), adjuvanted
- Development stage
- Approved
- Lead developer
- Dynavax Technologies
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Heplisav-B (Hepatitis B Vaccine [Recombinant], Adjuvanted) is a biologic vaccine developed by Dynavax Technologies for the prevention of infection caused by all known subtypes of the Hepatitis B virus in adults aged 18 and older. Approved by the FDA in 2018, it is a recombinant protein subunit vaccine that combines Hepatitis B surface antigen (HBsAg) with a proprietary synthetic cytosine phosphoguanine oligonucleotide adjuvant, CpG 1018. The CpG 1018 adjuvant acts as a Toll-like receptor 9 (TLR9) agonist, stimulating the innate immune system to enhance the adaptive immune response to the HBsAg. This adjuvanted formulation allows for a two-dose immunization series completed within one month, providing a more efficient alternative to traditional three-dose Hepatitis B vaccines.
- Brand names
- Heplisav-B
- Other names
- Hepatitis B Vaccine [Recombinant], Adjuvanted
02
Targets
TLR9 (Toll-like receptor 9)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis B vaccine (recombinant), adjuvanted.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B vaccine (recombinant), adjuvanted.